Scinai Immunotherapeutics Ltd.
- Biotech – industrial & Environmental
- Biotech or pharma, therapeutic R&D
- CMO, CRO
- Other products or services
Scinai operates two business units (BUs):
(1) An R&D BU focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases.
(2) A end-to-end CDMO BU, including preclinical to clinical process development, upscaling, analytical methods development and cGMP production.
With highly experienced pharmaceutical industry leadership, Scinai's R&D BU is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody pipeline.
The CDMO BU offers a menu of services aimed at biotech startup companies developing recombinant proteins using bacteria or yeast and looking for a boutique contractor to support them with manufacturing process development and optimization, development of analytical methods for in process controls and product release, scale up and GMP manufacturing (EMA/FDA standards) for clinical trials.